In Vivo Assessment of Antimicrobial Potential of Synthetic ANLP-V3 Peptide for the Treatment of Mastitis in a Mouse Model.
Source: PubMed, NCBI / U.S. National Library of Medicine
Therapeutic intervention in bovine mastitis faces significant challenges, primarily due to antimicrobial resistance (AMR) and formation of biofilms by etiological agents. Staphylococcus aureus (S. aureus), the most prevalent causative agent, has led to constant antibiotics failure due to development of multidrug-resistant (MDR) strains. Antimicrobial peptides (AMPs) have appeared as promising alternate. The current study evaluated AMP, ANLP-V3, for its therapeutic efficacy against mastitis induced by MDR S. aureus ATCC 700699 ex vivo in milk and in vivo mouse model. ANLP-V3 exhibited bactericidal nature in Minimum Bactericidal Concentration (MBC) assay and time dependent antibacterial activity in UHT milk. Thirty-six lactating Swiss albino mice were randomly divided into 6 groups (n = 6 per group) and infused by intramammary route. Groups I, II, and III were administered with normal saline, S. aureus ATCC 700699, and ANLP-V3 (100 µg), respectively. Groups IV, V, and VI were administered with ANLP-V3 prior infection, co-infusion with infection, and post-infection, respectively. All treatment groups showed approximately 1 logreduction in bacterial CFU compared to infection control. Histopathological examination revealed reduced inflammatory cell infiltration, mild pathological lesions and lower bacterial counts in ANLP-V3 treated groups compared to infection control. These findings suggest that ANLP-V3 could be a potential alternate for further investiga
Abstract
Therapeutic intervention in bovine mastitis faces significant challenges, primarily due to antimicrobial resistance (AMR) and formation of biofilms by etiological agents. Staphylococcus aureus (S. aureus), the most prevalent causative agent, has led to constant antibiotics failure due to development of multidrug-resistant (MDR) strains. Antimicrobial peptides (AMPs) have appeared as promising alternate. The current study evaluated AMP, ANLP-V3, for its therapeutic efficacy against mastitis induced by MDR S. aureus ATCC 700699 ex vivo in milk and in vivo mouse model. ANLP-V3 exhibited bactericidal nature in Minimum Bactericidal Concentration (MBC) assay and time dependent antibacterial activity in UHT milk. Thirty-six lactating Swiss albino mice were randomly divided into 6 groups (n = 6 per group) and infused by intramammary route. Groups I, II, and III were administered with normal saline, S. aureus ATCC 700699, and ANLP-V3 (100 µg), respectively. Groups IV, V, and VI were administered with ANLP-V3 prior infection, co-infusion with infection, and post-infection, respectively. All treatment groups showed approximately 1 logreduction in bacterial CFU compared to infection control. Histopathological examination revealed reduced inflammatory cell infiltration, mild pathological lesions and lower bacterial counts in ANLP-V3 treated groups compared to infection control. These findings suggest that ANLP-V3 could be a potential alternate for further investigation as a novel antimicrobial for managing MDR mastitis in bovines.